Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF-kappaB	B-protein
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti-inflammatory	B-protein
mediators	I-protein
.	O

The	O
role	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF-kappaB	B-protein
through	O
overexpression	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
IkappaBalpha	B-protein
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	B-cell_type
macrophages	I-cell_type
,	O
fibroblasts	B-cell_type
,	O
and	O
T	B-cell_type
cells	I-cell_type
infected	O
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
other	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
NF-kappaB	B-protein
-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti-inflammatory	B-protein
mediators	I-protein
,	O
like	O
IL-10	B-protein
and	I-protein
-11	I-protein
,	O
and	O
the	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B-protein
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B-protein
metalloproteinases	I-protein
1	I-protein
and	I-protein
3	I-protein
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O

Blocking	O
NF-kappaB	B-protein
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	B-cell_type
cells	I-cell_type
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

96	NULL
,	NULL
pp	NULL
.	NULL

5668-5673	NULL
,	NULL
May	NULL
1999	NULL
Immunology	NULL
Defining	NULL
therapeutic	NULL
targets	NULL
by	NULL
using	NULL
adenovirus	NULL
:	NULL
Blocking	NULL
NF-rB	NULL
inhibits	NULL
both	NULL
inflammatory	NULL
and	NULL
destructive	NULL
mechanisms	NULL
in	NULL
rheumatoid	NULL
synovium	NULL
but	NULL
spares	NULL
anti-inflammatory	NULL
mediators	NULL
JAN	NULL
BONDESON	NULL
,	NULL
BRIAN	NULL
FOXWELL	NULL
,	NULL
FIONULA	NULL
BRENNAN	NULL
,	NULL
AND	NULL
MARC	NULL
FELDMANN®*	NULL
Kennedy	NULL
Institute	NULL
of	NULL
Rheumatology	NULL
,	NULL
1	NULL
Aspenlea	NULL
Road	NULL
,	NULL
Hammersmith	NULL
,	NULL
London	NULL
W6	NULL
8LH	NULL
,	NULL
United	NULL
Kingdom	NULL
Edited	NULL
by	NULL
Anthony	NULL
Cerami	NULL
,	NULL
The	NULL
Kenneth	NULL
S.	NULL
Warren	NULL
Laboratories	NULL
,	NULL
Tarrytown	NULL
,	NULL
NY	NULL
,	NULL
and	NULL
approved	NULL
March	NULL
24	NULL
,	NULL
1999	NULL
(	NULL
received	NULL
for	NULL
review	NULL
January	NULL
25	NULL
,	NULL
1999	NULL
)	NULL
ABSTRACT	NULL
The	NULL
role	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-KB	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
has	NULL
long	NULL
been	NULL
a	NULL
subject	NULL
of	NULL
controversy	NULL
.	NULL

We	NULL
used	NULL
an	NULL
adenoviral	NULL
technique	NULL
of	NULL
blocking	NULL
NF-KB	NULL
through	NULL
overexpression	NULL
of	NULL
the	NULL
inhibitory	NULL
subunit	NULL
IxBa	NULL
,	NULL
which	NULL
has	NULL
the	NULL
advantage	NULL
that	NULL
it	NULL
can	NULL
be	NULL
used	NULL
in	NULL
the	NULL
diseased	NULL
tissue	NULL
itself	NULL
,	NULL
with	NULL
>	NULL
90	NULL
%	NULL
of	NULL
the	NULL
synovial	NULL
macrophages	NULL
,	NULL
fibroblasts	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
infected	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
other	NULL
pro-inflammatory	NULL
cytokines	NULL
is	NULL
NF-	NULL
«	NULL
B-dependent	NULL
in	NULL
rheumatoid	NULL
synovial	NULL
tissue	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
main	NULL
anti-inflammatory	NULL
mediators	NULL
,	NULL
like	NULL
IL-10	NULL
and	NULL
-11	NULL
,	NULL
and	NULL
the	NULL
IL-1	NULL
receptor	NULL
antago-nist	NULL
.	NULL

Of	NULL
even	NULL
more	NULL
interest	NULL
,	NULL
I	NULL
«	NULL
Ba	NULL
overexpression	NULL
inhibited	NULL
the	NULL
production	NULL
of	NULL
matrix	NULL
metalloproteinases	NULL
1	NULL
and	NULL
3	NULL
while	NULL
not	NULL
affecting	NULL
their	NULL
tissue	NULL
inhibitor	NULL
.	NULL

Blocking	NULL
NF-xB	NULL
in	NULL
the	NULL
rheumatoid	NULL
joint	NULL
thus	NULL
has	NULL
a	NULL
very	NULL
beneficial	NULL
profile	NULL
,	NULL
reducing	NULL
both	NULL
the	NULL
inflammatory	NULL
response	NULL
and	NULL
the	NULL
tissue	NULL
destruction	NULL
.	NULL

The	NULL
adenoviral	NULL
technique	NULL
described	NULL
here	NULL
has	NULL
widespread	NULL
applica-bility	NULL
,	NULL
allowing	NULL
rapid	NULL
testing	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
blocking	NULL
a	NULL
potential	NULL
therapeutic	NULL
target	NULL
in	NULL
either	NULL
cultures	NULL
of	NULL
normal	NULL
cells	NULL
or	NULL
in	NULL
the	NULL
diseased	NULL
tissue	NULL
itself	NULL
.	NULL

Despite	NULL
the	NULL
success	NULL
of	NULL
recent	NULL
clinical	NULL
trials	NULL
of	NULL
anti-tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNFa	NULL
)	NULL
therapy	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
,	NULL
based	NULL
on	NULL
the	NULL
prior	NULL
finding	NULL
that	NULL
TNFa	NULL
was	NULL
of	NULL
pivotal	NULL
importance	NULL
(	NULL
1-6	NULL
)	NULL
,	NULL
there	NULL
are	NULL
a	NULL
number	NULL
of	NULL
unresolved	NULL
questions	NULL
concerning	NULL
the	NULL
pathogenesis	NULL
of	NULL
RA	NULL
.	NULL

One	NULL
is	NULL
whether	NULL
the	NULL
mechanism	NULL
of	NULL
joint	NULL
inflammation	NULL
(	NULL
synovitis	NULL
)	NULL
and	NULL
destruction	NULL
are	NULL
the	NULL
same	NULL
or	NULL
whether	NULL
these	NULL
processes	NULL
are	NULL
regulated	NULL
differ-ently	NULL
.	NULL

Contrasting	NULL
opinions	NULL
concerning	NULL
this	NULL
have	NULL
been	NULL
argued	NULL
forcefully	NULL
:	NULL
For	NULL
example	NULL
,	NULL
one	NULL
school	NULL
of	NULL
thought	NULL
suggests	NULL
that	NULL
,	NULL
although	NULL
TNFa	NULL
is	NULL
the	NULL
cytokine	NULL
controlling	NULL
synovitis	NULL
,	NULL
IL-1	NULL
is	NULL
the	NULL
dominant	NULL
cytokine	NULL
implicated	NULL
in	NULL
cartilage	NULL
destruction	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Another	NULL
variant	NULL
suggests	NULL
that	NULL
the	NULL
fibroblast-like	NULL
cells	NULL
in	NULL
the	NULL
joint	NULL
,	NULL
its	NULL
major	NULL
source	NULL
of	NULL
destructive	NULL
enzymes	NULL
,	NULL
have	NULL
acquired	NULL
an	NULL
autonomous	NULL
``	NULL
tumor-like	NULL
``	NULL
invasive	NULL
phenotype	NULL
and	NULL
are	NULL
not	NULL
regulated	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
as	NULL
the	NULL
synovitis	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Transplantation	NULL
experiments	NULL
of	NULL
synovial	NULL
fibroblasts	NULL
and	NULL
cartilage	NULL
into	NULL
severe	NULL
combined	NULL
immunodeficient	NULL
mice	NULL
are	NULL
used	NULL
to	NULL
argue	NULL
this	NULL
point	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
prediction	NULL
from	NULL
these	NULL
experiments	NULL
is	NULL
that	NULL
anti-TNF	NULL
therapy	NULL
will	NULL
,	NULL
as	NULL
observed	NULL
in	NULL
trials	NULL
,	NULL
control	NULL
signs	NULL
and	NULL
symptoms	NULL
of	NULL
inflammation	NULL
but	NULL
may	NULL
not	NULL
prevent	NULL
structural	NULL
damage	NULL
and	NULL
consequential	NULL
deterioration	NULL
of	NULL
physical	NULL
function	NULL
in	NULL
the	NULL
long	NULL
term	NULL
.	NULL

The	NULL
anti-TNF	NULL
trials	NULL
reported	NULL
so	NULL
far	NULL
have	NULL
been	NULL
too	NULL
brief	NULL
to	NULL
resolve	NULL
this	NULL
controversy	NULL
.	NULL

A	NULL
deeper	NULL
understanding	NULL
of	NULL
the	NULL
pathogenesis	NULL
of	NULL
RA	NULL
would	NULL
help	NULL
determine	NULL
how	NULL
to	NULL
improve	NULL
on	NULL
antirheumatic	NULL
therapy	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
use	NULL
increasingly	NULL
sophisticated	NULL
molecular	NULL
methods	NULL
to	NULL
construct	NULL
and	NULL
analyze	NULL
animal	NULL
models	NULL
of	NULL
disease	NULL
by	NULL
using	NULL
transgenic	NULL
and/or	NULL
gene	NULL
targeting	NULL
technology	NULL
,	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
www.pnas.org	NULL
.	NULL

5668	NULL
the	NULL
study	NULL
of	NULL
animal	NULL
models	NULL
of	NULL
complex	NULL
multigenic	NULL
disease	NULL
can	NULL
only	NULL
reveal	NULL
clues	NULL
as	NULL
to	NULL
the	NULL
actual	NULL
mechanisms	NULL
operating	NULL
in	NULL
authentic	NULL
human	NULL
disease	NULL
.	NULL

We	NULL
have	NULL
begun	NULL
to	NULL
use	NULL
an	NULL
approach	NULL
,	NULL
applicable	NULL
in	NULL
either	NULL
normal	NULL
cells	NULL
or	NULL
pathological	NULL
tissues	NULL
from	NULL
diseased	NULL
sites	NULL
,	NULL
which	NULL
permits	NULL
the	NULL
inhibition	NULL
of	NULL
selected	NULL
intracellular	NULL
molecular	NULL
pathways	NULL
.	NULL

Blockade	NULL
is	NULL
achieved	NULL
through	NULL
our	NULL
effective	NULL
method	NULL
of	NULL
adenoviral	NULL
gene	NULL
transfer	NULL
into	NULL
normal	NULL
human	NULL
macrophages	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

This	NULL
method	NULL
has	NULL
now	NULL
enabled	NULL
us	NULL
to	NULL
analyze	NULL
in	NULL
detail	NULL
the	NULL
effects	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
blockade	NULL
in	NULL
rheumatoid	NULL
synovium	NULL
,	NULL
which	NULL
demonstrates	NULL
that	NULL
major	NULL
destructive	NULL
enzymes	NULL
,	NULL
chiefly	NULL
produced	NULL
by	NULL
fibroblasts	NULL
,	NULL
are	NULL
just	NULL
as	NULL
dependent	NULL
on	NULL
NF-KB	NULL
as	NULL
the	NULL
pro-inflammatory	NULL
cytokines	NULL
produced	NULL
mainly	NULL
by	NULL
macrophages	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
there	NULL
are	NULL
major	NULL
similarities	NULL
in	NULL
the	NULL
key	NULL
intracellular	NULL
pathways	NULL
in	NULL
the	NULL
cells	NULL
most	NULL
closely	NULL
involved	NULL
with	NULL
synovitis	NULL
,	NULL
the	NULL
macrophages	NULL
,	NULL
and	NULL
tissue	NULL
destruction	NULL
,	NULL
the	NULL
fibroblasts	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

Synovium	NULL
from	NULL
patients	NULL
with	NULL
RA	NULL
undergoing	NULL
joint	NULL
surgery	NULL
was	NULL
dissociated	NULL
by	NULL
cutting	NULL
into	NULL
small	NULL
pieces	NULL
and	NULL
was	NULL
digested	NULL
with	NULL
collagenase	NULL
and	NULL
DNase	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
total	NULL
cell	NULL
mixture	NULL
was	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
RPMI	NULL
medium	NULL
1640	NULL
with	NULL
25	NULL
mM	NULL
Hepes	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
on	NULL
24-	NULL
or	NULL
48-well	NULL
plates	NULL
.	NULL

Adenoviral	NULL
Vectors	NULL
.	NULL

Recombinant	NULL
,	NULL
replication-deficient	NULL
adenoviral	NULL
vectors	NULL
encoding	NULL
Escherichia	NULL
coli	NULL
B-galactosidase	NULL
(	NULL
Adv§	NULL
@	NULL
gal	NULL
)	NULL
or	NULL
having	NULL
no	NULL
insert	NULL
(	NULL
AdvO	NULL
)	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
A.	NULL
Byrnes	NULL
and	NULL
M.	NULL
Wood	NULL
(	NULL
Oxford	NULL
University	NULL
)	NULL
.	NULL

An	NULL
adenovirus	NULL
encoding	NULL
porcine	NULL
IxBa	NULL
with	NULL
a	NULL
cytomegalovirus	NULL
promoter	NULL
and	NULL
a	NULL
nuclear	NULL
localization	NULL
sequence	NULL
(	NULL
Advi	NULL
«	NULL
kBa	NULL
)	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
R.	NULL
de	NULL
Martin	NULL
(	NULL
University	NULL
of	NULL
Vienna	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Porcine	NULL
IxBa	NULL
has	NULL
>	NULL
95	NULL
%	NULL
homology	NULL
with	NULL
the	NULL
human	NULL
molecule	NULL
.	NULL

Viruses	NULL
were	NULL
propagated	NULL
in	NULL
the	NULL
293	NULL
human	NULL
embryonic	NULL
kidney	NULL
cell	NULL
line	NULL
and	NULL
were	NULL
purified	NULL
by	NULL
ultracentrifugation	NULL
through	NULL
two	NULL
cesium	NULL
chloride	NULL
gradients	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
titers	NULL
of	NULL
viral	NULL
stocks	NULL
were	NULL
determined	NULL
through	NULL
a	NULL
plaque	NULL
assay	NULL
on	NULL
293	NULL
cells	NULL
,	NULL
as	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

All	NULL
viruses	NULL
used	NULL
were	NULL
plaque-purified	NULL
from	NULL
a	NULL
master	NULL
stock	NULL
to	NULL
prevent	NULL
contamination	NULL
with	NULL
wild-type	NULL
adenovirus	NULL
.	NULL

Infection	NULL
Techniques	NULL
.	NULL

For	NULL
experiments	NULL
concerning	NULL
cytokine	NULL
or	NULL
matrix	NULL
metalloproteinase	NULL
synthesis	NULL
,	NULL
freshly	NULL
prepared	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
serum-free	NULL
RPMI	NULL
medium	NULL
1640	NULL
on	NULL
a	NULL
12-well	NULL
plate	NULL
at	NULL
2.5-4	NULL
million	NULL
cells	NULL
per	NULL
well	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
,	NULL
they	NULL
either	NULL
were	NULL
left	NULL
uninfected	NULL
or	NULL
were	NULL
infected	NULL
with	NULL
Advl	NULL
«	NULL
Ba	NULL
or	NULL
Adv0	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
This	NULL
paper	NULL
was	NULL
submitted	NULL
directly	NULL
(	NULL
Track	NULL
II	NULL
)	NULL
to	NULL
the	NULL
Proceedings	NULL
office	NULL
.	NULL

Abbreviations	NULL
:	NULL
Adv0	NULL
,	NULL
adenovirus	NULL
with	NULL
no	NULL
insert	NULL
;	NULL
AdvB	NULL
@	NULL
gal	NULL
,	NULL
adenovirus	NULL
encoding	NULL
AB-galactosidase	NULL
;	NULL
AdvI	NULL
«	NULL
Ba	NULL
,	NULL
adenovirus	NULL
encoding	NULL
porcine	NULL
IkBa	NULL
;	NULL
IL-1ra	NULL
,	NULL
interleukin	NULL
1	NULL
receptor	NULL
antagonist	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
RA	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
;	NULL
MMP	NULL
1	NULL
,	NULL
matrix	NULL
metalloproteinase	NULL
type	NULL
1	NULL
;	NULL
TIMP	NULL
,	NULL
tissue	NULL
inhibitor	NULL
of	NULL
metalloproteases	NULL
;	NULL
AP-1	NULL
,	NULL
activator	NULL
protein	NULL
1	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
m.feldmann	NULL
@	NULL
cxwms.ac.uk	NULL
.	NULL

Immunology	NULL
:	NULL
Bondeson	NULL
et	NULL
al	NULL
infection	NULL
of	NULL
40:1	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
removed	NULL
and	NULL
replaced	NULL
with	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
medium	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

The	NULL
nonadherent	NULL
cells	NULL
were	NULL
carefully	NULL
spun	NULL
down	NULL
and	NULL
were	NULL
reintroduced	NULL
to	NULL
the	NULL
rheumatoid	NULL
cell	NULL
coculture	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
medium	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
total	NULL
volume	NULL
,	NULL
thus	NULL
,	NULL
of	NULL
1	NULL
ml	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
were	NULL
infected	NULL
as	NULL
above	NULL
,	NULL
but	NULL
at	NULL
a	NULL
density	NULL
of	NULL
0.4	NULL
million	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
0.2	NULL
ml	NULL
,	NULL
on	NULL
a	NULL
96-well	NULL
plate	NULL
.	NULL

Four	NULL
wells	NULL
of	NULL
cells	NULL
from	NULL
each	NULL
category-uninfected	NULL
,	NULL
AdvO-infected	NULL
,	NULL
and	NULL
AdvlI	NULL
«	NULL
kBa-infected-were	NULL
plated	NULL
.	NULL

After	NULL
incubation	NULL
with	NULL
adenovirus	NULL
for	NULL
2	NULL
h	NULL
,	NULL
one	NULL
well	NULL
from	NULL
each	NULL
category	NULL
was	NULL
untreated	NULL
,	NULL
one	NULL
was	NULL
treated	NULL
with	NULL
20	NULL
ug/ml	NULL
of	NULL
human	NULL
recombinant	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
(	NULL
Cambridge	NULL
Bioscience	NULL
,	NULL
Cambridge	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
one	NULL
was	NULL
treated	NULL
with	NULL
20	NULL
ug/ml	NULL
of	NULL
the	NULL
AZ	NULL
anti-TNFa	NULL
antibody	NULL
(	NULL
Centocor	NULL
)	NULL
,	NULL
and	NULL
one	NULL
was	NULL
treated	NULL
with	NULL
both	NULL
of	NULL
these	NULL
cytokine	NULL
inhibitors	NULL
.	NULL

For	NULL
infectibility	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
0.6	NULL
ml	NULL
of	NULL
serum-free	NULL
RPMI	NULL
medium1640	NULL
on	NULL
a	NULL
24-well	NULL
plate	NULL
at	NULL
1	NULL
million	NULL
cells	NULL
per	NULL
well	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
,	NULL
they	NULL
either	NULL
were	NULL
left	NULL
uninfected	NULL
or	NULL
were	NULL
infected	NULL
with	NULL
Adv	NULL
@	NULL
gal	NULL
or	NULL
AdvO	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
40:1	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
removed	NULL
and	NULL
replaced	NULL
with	NULL
0.4	NULL
ml	NULL
of	NULL
RPMI	NULL
medium	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

The	NULL
nonadherent	NULL
cells	NULL
were	NULL
carefully	NULL
spun	NULL
down	NULL
and	NULL
were	NULL
reintroduced	NULL
to	NULL
the	NULL
rheumatoid	NULL
cell	NULL
coculture	NULL
in	NULL
0.2	NULL
ml	NULL
of	NULL
RPMI	NULL
medium	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
total	NULL
volume	NULL
of	NULL
0.6	NULL
ml	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Infectibility	NULL
.	NULL

Cell	NULL
were	NULL
scraped	NULL
off	NULL
the	NULL
plates	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
were	NULL
spun	NULL
down	NULL
and	NULL
washed	NULL
in	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
staining	NULL
solution	NULL
as	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Each	NULL
batch	NULL
of	NULL
uninfected	NULL
,	NULL
AdvO-infected	NULL
,	NULL
or	NULL
AdvBgal-infected	NULL
cells	NULL
then	NULL
was	NULL
resuspended	NULL
in	NULL
25	NULL
pl	NULL
of	NULL
staining	NULL
solution	NULL
and	NULL
was	NULL
incubated	NULL
with	NULL
125	NULL
ng	NULL
of	NULL
anti-CD3	NULL
PerCP	NULL
and	NULL
500	NULL
ng	NULL
of	NULL
anti-CD14	NULL
PE	NULL
(	NULL
both	NULL
from	NULL
Becton	NULL
Dickinson	NULL
)	NULL
,	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
45	NULL
pl	NULL
for	NULL
45	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

They	NULL
then	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
before	NULL
45	NULL
pl	NULL
of	NULL
a	NULL
2	NULL
mM	NULL
solution	NULL
of	NULL
Fluorescein	NULL
di-	NULL
(	NULL
B-D	NULL
)	NULL
-galactopyranoside	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
for	NULL
1	NULL
min	NULL
.	NULL

Addition	NULL
of	NULL
excess	NULL
(	NULL
10	NULL
%	NULL
)	NULL
ice-cold	NULL
staining	NULL
solution	NULL
was	NULL
used	NULL
to	NULL
stop	NULL
the	NULL
reaction	NULL
.	NULL

Cell	NULL
fluorescence	NULL
was	NULL
analyzed	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Cytokines	NULL
and	NULL
Metalloproteases	NULL
.	NULL

In	NULL
the	NULL
assays	NULL
for	NULL
cytokine	NULL
production	NULL
,	NULL
supernatants	NULL
were	NULL
taken	NULL
off	NULL
,	NULL
and	NULL
nonadherent	NULL
cells	NULL
were	NULL
removed	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

They	NULL
were	NULL
analyzed	NULL
for	NULL
TNFa	NULL
(	NULL
17	NULL
)	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-8	NULL
(	NULL
18	NULL
)	NULL
,	NULL
IL-10	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
,	NULL
IL-11	NULL
(	NULL
21	NULL
)	NULL
,	NULL
and	NULL
interleukin	NULL
1	NULL
receptor	NULL
antagonist	NULL
(	NULL
IL-1ra	NULL
)	NULL
and	NULL
the	NULL
p75	NULL
soluble	NULL
TNF	NULL
receptor	NULL
(	NULL
22	NULL
)	NULL
by	NULL
ELISA	NULL
.	NULL

The	NULL
production	NULL
of	NULL
matrix	NULL
metalloproteinase	NULL
type	NULL
1	NULL
(	NULL
MMP	NULL
1	NULL
)	NULL
(	NULL
Collagenase	NULL
)	NULL
,	NULL
MMP	NULL
3	NULL
(	NULL
Stromelysin	NULL
)	NULL
,	NULL
and	NULL
the	NULL
tissue	NULL
inhibitor	NULL
of	NULL
metalloproteases	NULL
(	NULL
TIMP-1	NULL
)	NULL
was	NULL
analyzed	NULL
by	NULL
ELISA	NULL
kits	NULL
purchased	NULL
from	NULL
Amersham	NULL
Pharmacia	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
aliquots	NULL
of	NULL
50	NULL
ul	NULL
were	NULL
taken	NULL
off	NULL
after	NULL
12	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
110	NULL
h.	NULL
After	NULL
the	NULL
nonadherent	NULL
cells	NULL
had	NULL
been	NULL
removed	NULL
and	NULL
reintroduced	NULL
to	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
medium	NULL
,	NULL
these	NULL
aliquots	NULL
were	NULL
analyzed	NULL
for	NULL
cytokines	NULL
and	NULL
metalloproteases	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Western	NULL
Blotting	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
three	NULL
batches	NULL
of	NULL
10	NULL
x	NULL
10°	NULL
cells	NULL
each	NULL
either	NULL
were	NULL
left	NULL
uninfected	NULL
or	NULL
were	NULL
infected	NULL
with	NULL
Adv0	NULL
or	NULL
Advi	NULL
«	NULL
kBa	NULL
.	NULL

Two	NULL
days	NULL
after	NULL
infection	NULL
,	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
23	NULL
)	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS/PAGE	NULL
on	NULL
a	NULL
10	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
polyacryl-amide	NULL
gel	NULL
,	NULL
followed	NULL
by	NULL
electrotransfer	NULL
onto	NULL
nitrocellulose	NULL
membranes	NULL
.	NULL

IxBa	NULL
and	NULL
the	NULL
p42/44	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
were	NULL
detected	NULL
by	NULL
using	NULL
antibodies	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

Statistical	NULL
Methods	NULL
.	NULL

All	NULL
statistical	NULL
testing	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
one-sided	NULL
,	NULL
paired-comparisons	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
5669	NULL
RESULTS	NULL
Infectibility	NULL
of	NULL
Rheumatoid	NULL
Synovial	NULL
Cells	NULL
with	NULL
Adenovirus	NULL
.	NULL

Infectibility	NULL
of	NULL
cells	NULL
derived	NULL
from	NULL
rheumatoid	NULL
synovial	NULL
tissue	NULL
was	NULL
investigated	NULL
by	NULL
using	NULL
the	NULL
AdvBGal	NULL
adenovirus	NULL
.	NULL

Because	NULL
40:1	NULL
of	NULL
AdvBGal	NULL
infected	NULL
95-100	NULL
%	NULL
of	NULL
human	NULL
macrophages	NULL
(	NULL
10	NULL
)	NULL
and	NULL
30:1	NULL
of	NULL
AdvBGal	NULL
infected	NULL
nearly	NULL
100	NULL
%	NULL
of	NULL
human	NULL
fibroblasts	NULL
(	NULL
J.B.	NULL
,	NULL
F.B	NULL
.	NULL

,	NULL
B.F.	NULL
,	NULL
and	NULL
MF	NULL
.	NULL

,	NULL
unpublished	NULL
work	NULL
)	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
use	NULL
10:1	NULL
and	NULL
40:1	NULL
of	NULL
AdvBGal	NULL
in	NULL
initial	NULL
experiments	NULL
.	NULL

It	NULL
was	NULL
found	NULL
that	NULL
40:1	NULL
of	NULL
AdvBGal	NULL
infected	NULL
nearly	NULL
100	NULL
%	NULL
of	NULL
the	NULL
entire	NULL
rheumatoid	NULL
synovial	NULL
cell	NULL
population	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
but	NULL
that	NULL
10:1	NULL
infected	NULL
only	NULL
60-70	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
subsequent	NULL
experiments	NULL
thus	NULL
used	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
40:1	NULL
of	NULL
AdvBGal	NULL
and	NULL
other	NULL
adenoviruses	NULL
.	NULL

Because	NULL
the	NULL
rheumatoid	NULL
synovium	NULL
is	NULL
a	NULL
complex	NULL
mixture	NULL
of	NULL
cells	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
study	NULL
the	NULL
infectibility	NULL
of	NULL
each	NULL
of	NULL
the	NULL
main	NULL
constituents	NULL
,	NULL
macrophages	NULL
,	NULL
T	NULL
lymphocytes	NULL
,	NULL
and	NULL
synovio-cytes	NULL
.	NULL

This	NULL
was	NULL
performed	NULL
through	NULL
preincubating	NULL
the	NULL
cells	NULL
with	NULL
fluorescent	NULL
antibody	NULL
markers	NULL
to	NULL
CD3	NULL
and	NULL
CD14	NULL
,	NULL
which	NULL
allowed	NULL
identification	NULL
of	NULL
CD3+/CD14-	NULL
(	NULL
T	NULL
lymphocytes	NULL
)	NULL
,	NULL
CD14+/CD3-	NULL
(	NULL
macrophages	NULL
)	NULL
,	NULL
and	NULL
CD3-/CD14-	NULL
(	NULL
chiefly	NULL
synovial	NULL
fibroblast	NULL
)	NULL
populations	NULL
.	NULL

By	NULL
using	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
and	NULL
human	NULL
skin	NULL
fibroblasts	NULL
as	NULL
controls	NULL
,	NULL
the	NULL
forward	NULL
scatter/side	NULL
scatter	NULL
characteristics	NULL
of	NULL
these	NULL
cell	NULL
populations	NULL
could	NULL
be	NULL
identified	NULL
.	NULL

Double	NULL
gating	NULL
then	NULL
was	NULL
used	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
rheumatoid	NULL
synovial	NULL
cell	NULL
populations	NULL
chosen	NULL
to	NULL
represent	NULL
T	NULL
lymphocytes	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
synoviocytes	NULL
had	NULL
the	NULL
correct	NULL
size/granularity	NULL
as	NULL
well	NULL
as	NULL
the	NULL
CD3-	NULL
CD14-	NULL
_	NULL
'	NULL
E	NULL
i.	NULL
R	NULL
CD14+	NULL
CD3	NULL
CD3+	NULL
CD14-	NULL
hm	NULL
20	NULL
f	NULL
C	NULL
4.0	NULL
60	NULL
so	NULL
100	NULL
%	NULL
cells	NULL
positive	NULL
for	NULL
Beta-gal	NULL
F	NULL
IxBa	NULL
A	NULL
p42/44	NULL
MAPK	NULL
Uninfected	NULL
AdvO	NULL
40:1	NULL
-	NULL
AdvikBa	NULL
40:1	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

In	NULL
excess	NULL
of	NULL
90	NULL
%	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
adenovirus	NULL
.	NULL

B-galactosidase	NULL
activity	NULL
in	NULL
total	NULL
rheumatoid	NULL
synovial	NULL
membrane	NULL
cell	NULL
cultures	NULL
(	NULL
4	NULL
)	NULL
,	NULL
T	NULL
lymphocytes	NULL
(	NULL
B	NULL
)	NULL
,	NULL
macrophages	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
synoviocytes	NULL
(	NULL
D	NULL
)	NULL
were	NULL
detected	NULL
by	NULL
double	NULL
gating	NULL
for	NULL
size/	NULL
granularity	NULL
and	NULL
cell	NULL
surface	NULL
markers	NULL
,	NULL
in	NULL
cultures	NULL
infected	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
AdvO	NULL
(	NULL
broken	NULL
line	NULL
)	NULL
or	NULL
Advf	NULL
@	NULL
gal	NULL
(	NULL
solid	NULL
line	NULL
}	NULL
.	NULL

Shown	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
five	NULL
experiments	NULL
.	NULL

In	NULL
E	NULL
,	NULL
the	NULL
means	NULL
of	NULL
B-galactosidase-positive	NULL
cells	NULL
are	NULL
plotted	NULL
+	NULL
SEM	NULL
(	NULL
#	NULL
=	NULL
5	NULL
)	NULL
.	NULL

In	NULL
F	NULL
,	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
AdvO	NULL
or	NULL
AdviIkBa	NULL
,	NULL
and	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

IxBa	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
Western	NULL
blotting	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
p42-44	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

5670	NULL
Immunology	NULL
:	NULL
Bondeson	NULL
et	NULL
al	NULL
surface	NULL
marker	NULL
characteristics	NULL
.	NULL

As	NULL
could	NULL
be	NULL
expected	NULL
from	NULL
earlier	NULL
results	NULL
,	NULL
both	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
and	NULL
fibroblasts	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
were	NULL
easy	NULL
to	NULL
infect	NULL
;	NULL
surprisingly	NULL
,	NULL
>	NULL
90	NULL
%	NULL
of	NULL
the	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
synovium	NULL
also	NULL
were	NULL
infected	NULL
by	NULL
40:1	NULL
of	NULL
AdvBGal	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

It	NULL
was	NULL
also	NULL
possible	NULL
to	NULL
demonstrate	NULL
that	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
AdvI	NULL
«	NULL
Ba	NULL
,	NULL
but	NULL
not	NULL
AdvO	NULL
,	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
considerable	NULL
cytosolic	NULL
overexpression	NULL
of	NULL
IxBa	NULL
(	NULL
Fig	NULL
.	NULL

1F	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
nuclear	NULL
protein	NULL
available	NULL
in	NULL
these	NULL
limited	NULL
amounts	NULL
of	NULL
tissue	NULL
did	NULL
not	NULL
permit	NULL
either	NULL
Western	NULL
analysis	NULL
of	NULL
nuclear	NULL
IxBa	NULL
or	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
studies	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
function	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
earlier	NULL
with	NULL
this	NULL
virus	NULL
by	NULL
using	NULL
human	NULL
macrophages	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

IxBa	NULL
Overexpression	NULL
Inhibits	NULL
the	NULL
Production	NULL
of	NULL
Pro-Inflammatory	NULL
Cytokines	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
TNFa	NULL
,	NULL
by	NULL
rheumatoid	NULL
synovium	NULL
as	NULL
assessed	NULL
two	NULL
days	NULL
after	NULL
infection	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
70	NULL
%	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
Advl	NULL
«	NULL
Ba	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
mock-infected	NULL
cells	NULL
or	NULL
cells	NULL
infected	NULL
with	NULL
AdvO	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
both	NULL
IL-1	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
and	NULL
IL-8	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
also	NULL
was	NULL
inhibited	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
by	NULL
IxBa	NULL
over-expression	NULL
,	NULL
but	NULL
to	NULL
a	NULL
more	NULL
modest	NULL
degree	NULL
(	NULL
40	NULL
%	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
uninfected	NULL
or	NULL
AdvO-infected	NULL
cells	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IL-6	NULL
was	NULL
inhibited	NULL
very	NULL
potently	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
(	NULL
85	NULL
%	NULL
;	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
agree	NULL
with	NULL
previous	NULL
findings	NULL
in	NULL
normal	NULL
macrophages	NULL
identifying	NULL
IL-6	NULL
as	NULL
a	NULL
pro-inflammatory	NULL
cytokine	NULL
strongly	NULL
dependent	NULL
on	NULL
transcriptional	NULL
regulation	NULL
by	NULL
NF-kB	NULL
11	NULL
)	NULL
.	NULL

In	NULL
a	NULL
separate	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
aliquots	NULL
of	NULL
medium	NULL
from	NULL
cultured	NULL
cells	NULL
from	NULL
rheumatoid	NULL
synovial	NULL
membranes	NULL
were	NULL
removed	NULL
after	NULL
12	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
110	NULL
h	NULL
,	NULL
and	NULL
cytokine	NULL
analysis	NULL
was	NULL
performed	NULL
.	NULL

It	NULL
was	NULL
seen	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
that	NULL
,	NULL
although	NULL
the	NULL
production	NULL
of	NULL
TNFa	NULL
and	NULL
IL-6	NULL
from	NULL
uninfected	NULL
or	NULL
AdvO-infected	NULL
cells	NULL
gradually	NULL
increased	NULL
between	NULL
day	NULL
1	NULL
and	NULL
day	NULL
5	NULL
,	NULL
the	NULL
cytokine	NULL
production	NULL
from	NULL
AdviI	NULL
«	NULL
Ba-infected	NULL
cells	NULL
remained	NULL
almost	NULL
static	NULL
,	NULL
indicating	NULL
that	NULL
,	NULL
once	NULL
sufficient	NULL
over-expression	NULL
of	NULL
IxBa	NULL
had	NULL
been	NULL
achieved	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
only	NULL
very	NULL
little	NULL
TNFa	NULL
and	NULL
IL-6	NULL
is	NULL
produced	NULL
.	NULL

IxBa	NULL
Overexpression	NULL
Does	NULL
Not	NULL
Affect	NULL
the	NULL
Production	NULL
of	NULL
the	NULL
Major	NULL
Anti-Inflammatory	NULL
Cytokines	NULL
and	NULL
Mediators	NULL
.	NULL

Previous	NULL
results	NULL
from	NULL
human	NULL
macrophages	NULL
,	NULL
the	NULL
major	NULL
producers	NULL
of	NULL
IL-10	NULL
in	NULL
the	NULL
rheumatoid	NULL
joint	NULL
(	NULL
24	NULL
)	NULL
,	NULL
have	NULL
indicated	NULL
that	NULL
both	NULL
IL-10	NULL
and	NULL
the	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
are	NULL
NF-	NULL
«	NULL
B	NULL
800	NULL
A	NULL
600	NULL
400	NULL
IL-1	NULL
,	NULL
pg/ml	NULL
200	NULL
3000	NULL
IL-8	NULL
,	NULL
pg/ml	NULL
2000	NULL
1000	NULL
IL-6	NULL
,	NULL
pg/ml	NULL
AdvO	NULL
40:1	NULL
AdvikBa	NULL
40:1	NULL
Treatment	NULL
Uninfected	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

AdvikBa	NULL
infection	NULL
inhibits	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
from	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
effect	NULL
of	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
Adv0	NULL
or	NULL
AdvikBa	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
IL-18	NULL
(	NULL
4	NULL
)	NULL
,	NULL
IL-8	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
IL-6	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
3000	NULL
-	NULL
£	NULL
BD	NULL
2000	NULL
E	NULL
Z	NULL
E	NULL
1000	NULL
-	NULL
7	NULL
0	NULL
r	NULL
1	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
30000	NULL
~	NULL
B	NULL
€	NULL
mp	NULL
20000	NULL
7	NULL
€	NULL
fal	NULL
H	NULL
10000	NULL
7	NULL
1	NULL
0	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
IxBa	NULL
over-expression	NULL
permanently	NULL
inhibits	NULL
TNFa	NULL
and	NULL
IL-6	NULL
production	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
effect	NULL
of	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
Adv0	NULL
or	NULL
AdvikBa	NULL
«	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
TNFa	NULL
(	NULL
4	NULL
)	NULL
or	NULL
IL-6	NULL
(	NULL
B	NULL
)	NULL
over	NULL
time	NULL
.	NULL

Symbols	NULL
denote	NULL
uninfected	NULL
(	NULL
M	NULL
)	NULL
,	NULL
AdvO-infected	NULL
(	NULL
#	NULL
)	NULL
,	NULL
or	NULL
AdvIkBa-infected	NULL
(	NULL
@	NULL
)	NULL
cells	NULL
.	NULL

Shown	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

independent	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
profound	NULL
diminution	NULL
of	NULL
TNFa	NULL
and	NULL
IL-1B	NULL
induced	NULL
by	NULL
NF-kB	NULL
down-regulation	NULL
in	NULL
macrophages	NULL
causes	NULL
a	NULL
modest	NULL
secondary	NULL
decrease	NULL
in	NULL
IL-10	NULL
and	NULL
IL-1ra	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
rheumatoid	NULL
synovial	NULL
cell	NULL
cultures	NULL
,	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
both	NULL
IL-10	NULL
and	NULL
the	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
are	NULL
unaffected	NULL
by	NULL
over-expression	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
production	NULL
of	NULL
the	NULL
p75	NULL
soluble	NULL
TNF	NULL
receptor	NULL
was	NULL
inhibited	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
however	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

IL-11	NULL
,	NULL
Ts	NULL
_TA	NULL
E	NULL
200	NULL
--	NULL
C	NULL
:	NULL
a.	NULL
é	NULL
100	NULL
E	NULL
0	NULL
-	NULL
U	NULL
2m	NULL
!	NULL

B	NULL
§	NULL
>	NULL
!	NULL

;	NULL
£0	NULL
``	NULL
|	NULL
a	NULL
®	NULL
|	NULL
W	NULL
a	NULL
-	NULL
-	NULL
1	NULL
g	NULL
:	NULL
1000	NULL
--	NULL
T	NULL
C	NULL
fik	NULL
-	NULL
800	NULL
Allg	NULL
i	NULL
in	NULL
§	NULL
§	NULL
:	NULL
J	NULL
;	NULL
200	NULL
~|	NULL
=	NULL
o	NULL
**	NULL
$	NULL
0000	NULL
7	NULL
D	NULL
@	NULL
40000	NULL
1	NULL
FU	NULL
Em	NULL
=|	NULL
20000	NULL
7	NULL
m	NULL
10000	NULL
7	NULL
Uninfected	NULL
AdvO	NULL
40:1	NULL
AdvicBa	NULL
40:1	NULL
Treatment	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
AdvI	NULL
«	NULL
Ba	NULL
infection	NULL
has	NULL
only	NULL
marginal	NULL
effects	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
anti-inflammatory	NULL
mediators	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
effect	NULL
of	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
AdvO	NULL
or	NULL
AdvI	NULL
«	NULL
Ba	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
IL-10	NULL
(	NULL
4	NULL
)	NULL
,	NULL
the	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
(	NULL
B	NULL
)	NULL
,	NULL
the	NULL
p75	NULL
soluble	NULL
TNF	NULL
receptor	NULL
(	NULL
C	NULL
)	NULL
,	NULL
and	NULL
IL-11	NULL
(	NULL
D	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

Immunology	NULL
:	NULL
Bondeson	NULL
et	NULL
al	NULL
_L	NULL
0300	NULL
7	NULL
E	NULL
§	NULL
;	NULL
]	NULL
_L	NULL
A	NULL
ie	NULL
200	NULL
g	NULL
a	NULL
-	NULL
10	NULL
7	NULL
_	NULL
IL	NULL
‘	NULL
JDULIJO	NULL
7	NULL
E00	NULL
|	NULL
als	NULL
$	NULL
m	NULL
»	NULL
-	NULL
B	NULL
«	NULL
f	NULL
A	NULL
fie	NULL
#	NULL
,	NULL
10000	NULL
7	NULL
|J	NULL
;	NULL
]	NULL
#	NULL
4	NULL
0	NULL
:	NULL
C	NULL
400	NULL
§	NULL
»	NULL
_L	NULL
f	NULL
=	NULL
200	NULL
||	NULL
Z	NULL
|	NULL
E	NULL
100	NULL
7	NULL
E	NULL
[	NULL
|	NULL
Uninfected	NULL
Advo	NULL
40:1	NULL
AdvikBa	NULL
40:1	NULL
Treatment	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

IxBa	NULL
over-expression	NULL
potently	NULL
inhibits	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
production	NULL
but	NULL
slightly	NULL
potentiates	NULL
the	NULL
production	NULL
of	NULL
TIMP-1	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
effect	NULL
of	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
Adv0	NULL
or	NULL
AdvikBa	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
MMP	NULL
1	NULL
(	NULL
4	NULL
)	NULL
,	NULL
MMP	NULL
3	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
TIMP-1	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
SEM	NULL
(	NULL
r	NULL
=	NULL
6	NULL
)	NULL
.	NULL

another	NULL
important	NULL
immunoregulatory	NULL
cytokine	NULL
produced	NULL
mainly	NULL
by	NULL
the	NULL
fibroblast-like	NULL
cells	NULL
in	NULL
the	NULL
rheumatoid	NULL
synovium	NULL
(	NULL
21	NULL
)	NULL
,	NULL
was	NULL
up-regulated	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
down-regulation	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
the	NULL
classical	NULL
pro-inflammatory	NULL
cytokines	NULL
(	NULL
TNFa	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
)	NULL
are	NULL
NF-	NULL
«	NULL
B-dependent	NULL
whereas	NULL
the	NULL
anti-inflammatory	NULL
ones	NULL
(	NULL
IL-10	NULL
,	NULL
IL-11	NULL
)	NULL
are	NULL
not	NULL
.	NULL

IxBa	NULL
Overexpression	NULL
Inhibits	NULL
the	NULL
Production	NULL
of	NULL
Matrix	NULL
Metalloproteases	NULL
but	NULL
Not	NULL
Their	NULL
Inhibitor	NULL
.	NULL

It	NULL
was	NULL
observed	NULL
160	NULL
7	NULL
A	NULL
_	NULL
140	NULL
-I	NULL
G	NULL
[	NULL
%	NULL
120	NULL
7	NULL
bel	NULL
<	NULL
100	NULL
7	NULL
&	NULL
80	NULL
3	NULL
1	NULL
Z	NULL
60	NULL
7	NULL
4	NULL
--	NULL
--	NULL
g____-_	NULL
--	NULL
_	NULL
--	NULL
-	NULL
@	NULL
40	NULL
7	NULL
t	NULL
t	NULL
t	NULL
t	NULL
t	NULL
I	NULL
*	NULL
o	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
30000	NULL
7	NULL
©	NULL
B	NULL
BP	NULL
=	NULL
20000	NULL
7	NULL
o	NULL
(	NULL
2	NULL
10000	NULL
7|	NULL
a	NULL
./	NULL
‘	NULL
/./.—o	NULL
0—	NULL
t	NULL
t	NULL
t	NULL
1	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1000	NULL
7	NULL
€	NULL
]	NULL
C	NULL
E	NULL
;	NULL
800	NULL
-	NULL
1	NULL
-s	NULL
_	NULL
600	NULL
s	NULL
=	NULL
F	NULL
400	NULL
7	NULL
t	NULL
t	NULL
t	NULL
t	NULL
t	NULL
I	NULL
*	NULL
``	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Day	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
AdvikBa	NULL
infection	NULL
on	NULL
the	NULL
balance	NULL
between	NULL
MMP	NULL
production	NULL
versus	NULL
the	NULL
production	NULL
of	NULL
TIMP-1	NULL
over	NULL
time	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
effect	NULL
of	NULL
infection	NULL
of	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
with	NULL
40:1	NULL
of	NULL
either	NULL
AdvO	NULL
or	NULL
AdvI	NULL
«	NULL
Ba	NULL
on	NULL
the	NULL
spontaneous	NULL
production	NULL
MMP	NULL
1	NULL
(	NULL
4	NULL
)	NULL
,	NULL
MMP	NULL
3	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
TIMP-1	NULL
(	NULL
C	NULL
)	NULL
over	NULL
time	NULL
.	NULL

Symbols	NULL
denote	NULL
uninfected	NULL
(	NULL
@	NULL
)	NULL
,	NULL
AdvO-infected	NULL
(	NULL
#	NULL
)	NULL
,	NULL
or	NULL
AdvI	NULL
«	NULL
Ba-infected	NULL
(	NULL
@	NULL
)	NULL
cells	NULL
.	NULL

Shown	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
5671	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
4	NULL
and	NULL
B	NULL
)	NULL
that	NULL
IxBa	NULL
overexpression	NULL
potently	NULL
inhibited	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
both	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
in	NULL
rheumatoid	NULL
synovial	NULL
cells	NULL
.	NULL

These	NULL
MMPs	NULL
were	NULL
assayed	NULL
because	NULL
there	NULL
is	NULL
evidence	NULL
that	NULL
they	NULL
are	NULL
produced	NULL
in	NULL
RA	NULL
joints	NULL
and	NULL
are	NULL
important	NULL
mediators	NULL
in	NULL
joint	NULL
destruction	NULL
(	NULL
25-28	NULL
)	NULL
;	NULL
quantitative	NULL
ELISA	NULL
assays	NULL
are	NULL
available	NULL
to	NULL
measure	NULL
their	NULL
biosynthesis	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
spontaneous	NULL
production	NULL
of	NULL
their	NULL
inducible	NULL
inhibitor	NULL
,	NULL
TIMP-1	NULL
,	NULL
was	NULL
not	NULL
significantly	NULL
affected	NULL
after	NULL
2	NULL
days	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
while	NULL
studying	NULL
a	NULL
time-course	NULL
of	NULL
MMP	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
and	NULL
B	NULL
)	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
,	NULL
although	NULL
uninfected	NULL
and	NULL
AdvO-infected	NULL
rheumatoid	NULL
synovial	NULL
cell	NULL
cocultures	NULL
continue	NULL
producing	NULL
these	NULL
enzymes	NULL
throughout	NULL
the	NULL
incubation	NULL
period	NULL
,	NULL
the	NULL
AdvI	NULL
«	NULL
Ba-infected	NULL
cells	NULL
produce	NULL
very	NULL
little	NULL
of	NULL
either	NULL
MMP	NULL
1	NULL
or	NULL
MMP	NULL
3	NULL
after	NULL
significant	NULL
IxBa	NULL
overexpression	NULL
has	NULL
been	NULL
achieved	NULL
.	NULL

Again	NULL
,	NULL
there	NULL
is	NULL
a	NULL
remarkable	NULL
contrast	NULL
to	NULL
the	NULL
strong	NULL
potentiation	NULL
of	NULL
TIMP-1	NULL
production	NULL
seen	NULL
after	NULL
3	NULL
or	NULL
5	NULL
days	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Figs	NULL
.	NULL

5-6	NULL
indicate	NULL
direct	NULL
or	NULL
indirect	NULL
dependence	NULL
of	NULL
NF-KB	NULL
for	NULL
the	NULL
production	NULL
of	NULL
both	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
,	NULL
but	NULL
not	NULL
for	NULL
TIMP-1	NULL
.	NULL

Both	NULL
IL-1	NULL
and	NULL
TNFa	NULL
are	NULL
known	NULL
inducers	NULL
of	NULL
MMPs	NULL
,	NULL
however	NULL
,	NULL
and	NULL
to	NULL
examine	NULL
the	NULL
influence	NULL
of	NULL
the	NULL
down-regulation	NULL
of	NULL
these	NULL
two	NULL
cytokines	NULL
on	NULL
MMP	NULL
production	NULL
,	NULL
a	NULL
series	NULL
of	NULL
experiments	NULL
was	NULL
performed	NULL
with	NULL
addition	NULL
of	NULL
IL-1ra	NULL
and/or	NULL
a	NULL
TNFa	NULL
neutralizing	NULL
antibody	NULL
just	NULL
after	NULL
infection	NULL
of	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
seen	NULL
(	NULL
Fig	NULL
.	NULL

74	NULL
)	NULL
that	NULL
,	NULL
although	NULL
IL-1	NULL
turned	NULL
out	NULL
to	NULL
be	NULL
a	NULL
major	NULL
inducer	NULL
of	NULL
MMP	NULL
1	NULL
,	NULL
the	NULL
relative	NULL
inhibition	NULL
of	NULL
MMP	NULL
1	NULL
by	NULL
IxBa	NULL
over-expression	NULL
was	NULL
largely	NULL
unaffected	NULL
by	NULL
neutralization	NULL
of	NULL
either	NULL
IL-1	NULL
or	NULL
TNFa	NULL
.	NULL

Although	NULL
inhibition	NULL
of	NULL
A	NULL
IL-	NULL
Ira	NULL
and	NULL
anti-TNF	NULL
antibody	NULL
Anti-	NULL
TNF	NULL
antibody	NULL
IL-Ira	NULL
No	NULL
anne	NULL
»	NULL
inhibitor	NULL
.	NULL

IL-	NULL
Iru	NULL
and	NULL
anti-TNF	NULL
antibody	NULL
Anti-TNF	NULL
‘	NULL
antibody	NULL
No	NULL
inhibitor	NULL
anti-TNF	NULL
IL-Ira	NULL
and	NULL
‘	NULL
antibody	NULL
Anti-TNF	NULL
|	NULL
antibody	NULL
No	NULL
inhibitor	NULL
a	NULL
100	NULL
200	NULL
TIMP	NULL
,	NULL
ng/mi	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
AdvI	NULL
«	NULL
Ba	NULL
infection	NULL
on	NULL
MMP	NULL
and	NULL
TIMP	NULL
production	NULL
in	NULL
rheumatoid	NULL
synovial	NULL
cell	NULL
cultures	NULL
in	NULL
which	NULL
IL-1	NULL
and/or	NULL
TNFa	NULL
were	NULL
neutralized	NULL
.	NULL

Rheumatoid	NULL
synovial	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
uninfected	NULL
or	NULL
infected	NULL
with	NULL
40:1	NULL
of	NULL
Adv0	NULL
or	NULL
AdvI	NULL
«	NULL
Ba	NULL
.	NULL

After	NULL
the	NULL
virus	NULL
was	NULL
taken	NULL
off	NULL
and	NULL
culture	NULL
medium	NULL
was	NULL
added	NULL
,	NULL
the	NULL
cells	NULL
in	NULL
each	NULL
of	NULL
the	NULL
three	NULL
categories	NULL
either	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
20	NULL
ug/ml	NULL
of	NULL
the	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
and/or	NULL
20	NULL
ug/ml	NULL
of	NULL
the	NULL
A2	NULL
anti-TNFa	NULL
antibody	NULL
.	NULL

The	NULL
spontaneous	NULL
production	NULL
of	NULL
MMP	NULL
1	NULL
(	NULL
4	NULL
)	NULL
,	NULL
MMP	NULL
3	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
TIMP-1	NULL
(	NULL
C	NULL
)	NULL
was	NULL
assayed	NULL
after	NULL
2	NULL
days	NULL
.	NULL

Shown	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
complete	NULL
experiments	NULL
.	NULL

5672	NULL
Immunology	NULL
:	NULL
Bondeson	NULL
et	NULL
al	NULL
IL-1	NULL
through	NULL
IxBa	NULL
overexpression	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
may	NULL
contribute	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
MMP	NULL
1	NULL
is	NULL
~50	NULL
%	NULL
under	NULL
direct	NULL
NF-KB	NULL
control	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

74	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-1ra	NULL
,	NULL
there	NULL
is	NULL
still	NULL
50	NULL
%	NULL
inhibition	NULL
in	NULL
Advl	NULL
«	NULL
Ba-infected	NULL
cells	NULL
)	NULL
,	NULL
although	NULL
it	NULL
can	NULL
not	NULL
be	NULL
definitely	NULL
ruled	NULL
out	NULL
that	NULL
indirect	NULL
effects	NULL
on	NULL
some	NULL
other	NULL
soluble	NULL
mediator	NULL
might	NULL
be	NULL
involved	NULL
.	NULL

MMP	NULL
3	NULL
was	NULL
even	NULL
more	NULL
potently	NULL
driven	NULL
by	NULL
IL-1	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Neutralization	NULL
of	NULL
IL-1	NULL
removed	NULL
the	NULL
inhibition	NULL
of	NULL
MMP	NULL
3	NULL
seen	NULL
in	NULL
AdvI	NULL
«	NULL
Ba-infected	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
MMP	NULL
3	NULL
down-regulation	NULL
by	NULL
IxBa	NULL
overexpression	NULL
is	NULL
caused	NULL
by	NULL
inhibition	NULL
of	NULL
IL-1	NULL
.	NULL

Although	NULL
TIMP-1	NULL
appeared	NULL
to	NULL
be	NULL
partly	NULL
IL-1	NULL
driven	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
,	NULL
AdvI	NULL
«	NULL
Ba	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
TIMP-1	NULL
production	NULL
under	NULL
either	NULL
of	NULL
the	NULL
conditions	NULL
studied	NULL
.	NULL

DISCUSSION	NULL
The	NULL
genetic	NULL
approach	NULL
to	NULL
studying	NULL
cell	NULL
signaling	NULL
pathways	NULL
has	NULL
many	NULL
advantages	NULL
and	NULL
has	NULL
led	NULL
to	NULL
marked	NULL
progress	NULL
and	NULL
deeper	NULL
understanding	NULL
of	NULL
signal	NULL
transduction	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
only	NULL
applies	NULL
to	NULL
cells	NULL
that	NULL
are	NULL
easy	NULL
to	NULL
transfect	NULL
efficiently	NULL
,	NULL
for	NULL
example	NULL
,	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
CV-1	NULL
origin	NULL
SV-40	NULL
(	NULL
COS	NULL
)	NULL
,	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
,	NULL
293	NULL
,	NULL
or	NULL
Jurkat	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
assumed	NULL
,	NULL
or	NULL
hoped	NULL
,	NULL
that	NULL
other	NULL
cell	NULL
types	NULL
will	NULL
conform	NULL
to	NULL
the	NULL
principles	NULL
determined	NULL
in	NULL
cell	NULL
lines	NULL
.	NULL

There	NULL
are	NULL
a	NULL
number	NULL
of	NULL
reasons	NULL
why	NULL
this	NULL
may	NULL
not	NULL
be	NULL
the	NULL
case	NULL
,	NULL
which	NULL
prompted	NULL
us	NULL
to	NULL
develop	NULL
a	NULL
method	NULL
of	NULL
using	NULL
adenovirus	NULL
to	NULL
introduce	NULL
genes	NULL
into	NULL
effectively	NULL
all	NULL
(	NULL
>	NULL
95	NULL
%	NULL
)	NULL
normal	NULL
human	NULL
macrophages	NULL
,	NULL
thus	NULL
permitting	NULL
us	NULL
to	NULL
study	NULL
the	NULL
effects	NULL
of	NULL
blocking	NULL
signaling	NULL
pathways	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
of	NULL
major	NULL
importance	NULL
in	NULL
chronic	NULL
inflammation	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
extended	NULL
the	NULL
use	NULL
of	NULL
adenoviral	NULL
gene	NULL
transfer	NULL
and	NULL
have	NULL
demonstrate	NULL
that	NULL
all	NULL
major	NULL
cell	NULL
types	NULL
in	NULL
a	NULL
pathological	NULL
site	NULL
,	NULL
the	NULL
rheumatoid	NULL
synovium	NULL
,	NULL
are	NULL
infected	NULL
at	NULL
a	NULL
very	NULL
high	NULL
frequency	NULL
.	NULL

This	NULL
means	NULL
that	NULL
adenovirus	NULL
is	NULL
a	NULL
useful	NULL
tool	NULL
for	NULL
studying	NULL
not	NULL
only	NULL
signaling	NULL
in	NULL
the	NULL
macrophages	NULL
,	NULL
but	NULL
also	NULL
the	NULL
T	NULL
lymphocytes	NULL
and	NULL
cells	NULL
lacking	NULL
markers	NULL
of	NULL
T	NULL
cells	NULL
or	NULL
macrophages	NULL
,	NULL
which	NULL
would	NULL
include	NULL
mainly	NULL
fibroblasts	NULL
with	NULL
some	NULL
dendritic	NULL
cells	NULL
and	NULL
endothelium	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
marked	NULL
infectibility	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
rheumatoid	NULL
joint	NULL
was	NULL
surprising	NULL
in	NULL
view	NULL
of	NULL
reports	NULL
in	NULL
the	NULL
literature	NULL
of	NULL
low	NULL
infectibility	NULL
of	NULL
in	NULL
vitro	NULL
activated	NULL
T	NULL
lymphocytes	NULL
(	NULL
31	NULL
)	NULL
.	NULL

However	NULL
,	NULL
other	NULL
authors	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
have	NULL
reported	NULL
greater	NULL
infectibility	NULL
,	NULL
provided	NULL
that	NULL
a	NULL
targeting	NULL
antibody	NULL
was	NULL
used	NULL
;	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
exact	NULL
state	NULL
of	NULL
activation	NULL
of	NULL
the	NULL
T	NULL
lymphocyte	NULL
,	NULL
and	NULL
which	NULL
integrins	NULL
and	NULL
other	NULL
receptors	NULL
are	NULL
expressed	NULL
,	NULL
is	NULL
of	NULL
importance	NULL
for	NULL
increasing	NULL
infectability	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
reduction	NULL
in	NULL
synthesis	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
in	NULL
RA	NULL
synovium	NULL
treated	NULL
with	NULL
AdvI	NULL
«	NULL
Ba	NULL
varied	NULL
with	NULL
the	NULL
cytokine	NULL
assayed	NULL
.	NULL

At	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
IL-18B	NULL
and	NULL
IL-8	NULL
production	NULL
was	NULL
reduced	NULL
by	NULL
40	NULL
%	NULL
whereas	NULL
TNFa	NULL
was	NULL
reduced	NULL
by	NULL
75	NULL
%	NULL
and	NULL
IL-6	NULL
was	NULL
reduced	NULL
by	NULL
85	NULL
%	NULL
.	NULL

Kinetic	NULL
studies	NULL
for	NULL
the	NULL
latter	NULL
two	NULL
show	NULL
that	NULL
the	NULL
exact	NULL
degree	NULL
of	NULL
inhibition	NULL
varies	NULL
with	NULL
time	NULL
and	NULL
sample	NULL
of	NULL
diseased	NULL
tissue	NULL
.	NULL

However	NULL
,	NULL
the	NULL
differential	NULL
degree	NULL
of	NULL
inhibition	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
induced	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
blockade	NULL
suggests	NULL
that	NULL
there	NULL
are	NULL
both	NULL
NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
NF-	NULL
«	NULL
B-independent	NULL
pathways	NULL
involved	NULL
in	NULL
regulating	NULL
the	NULL
pro-inflammatory	NULL
cytokines	NULL
produced	NULL
in	NULL
the	NULL
rheumatoid	NULL
joint	NULL
.	NULL

It	NULL
will	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
analyze	NULL
what	NULL
these	NULL
other	NULL
important	NULL
transcription	NULL
factors	NULL
are	NULL
.	NULL

Both	NULL
activator	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
and	NULL
NF-IL-6	NULL
are	NULL
likely	NULL
candidates	NULL
.	NULL

That	NULL
there	NULL
are	NULL
indeed	NULL
both	NULL
NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
pathways	NULL
of	NULL
inducing	NULL
TNFa	NULL
and	NULL
other	NULL
pro-inflammatory	NULL
cytokines	NULL
in	NULL
macrophages	NULL
has	NULL
been	NULL
clearly	NULL
demonstrated	NULL
by	NULL
using	NULL
AdvlI	NULL
«	NULL
Ba	NULL
as	NULL
an	NULL
inhibitor	NULL
:	NULL
Although	NULL
lipopolysaccharide-induced	NULL
TNFa	NULL
was	NULL
NF-	NULL
«	NULL
B-dependent	NULL
in	NULL
human	NULL
macrophages	NULL
,	NULL
zymosan-induced	NULL
TNFa	NULL
was	NULL
not	NULL
(	NULL
11	NULL
)	NULL
,	NULL
and	NULL
there	NULL
are	NULL
NF-	NULL
«	NULL
B-independent	NULL
pathways	NULL
of	NULL
inducing	NULL
TNFa	NULL
also	NULL
in	NULL
T	NULL
lymphocytes	NULL
(	NULL
34	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
,	NULL
in	NULL
active	NULL
RA	NULL
synovium	NULL
,	NULL
both	NULL
pro-inflammatory	NULL
cytokines	NULL
and	NULL
anti-inflammatory	NULL
mediators	NULL
such	NULL
as	NULL
TGFR1	NULL
,	NULL
IL-10	NULL
,	NULL
IL-1ra	NULL
,	NULL
and	NULL
the	NULL
soluble	NULL
TNF-receptors	NULL
are	NULL
up-regulated	NULL
and	NULL
spontaneously	NULL
produced	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Because	NULL
there	NULL
is	NULL
persistent	NULL
disease	NULL
despite	NULL
the	NULL
production	NULL
of	NULL
these	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
anti-inflammatory	NULL
molecules	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
predominate	NULL
;	NULL
it	NULL
is	NULL
thus	NULL
of	NULL
great	NULL
interest	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
NF-kB	NULL
blockade	NULL
was	NULL
markedly	NULL
different	NULL
on	NULL
pro-inflammatory	NULL
mediators	NULL
than	NULL
on	NULL
anti-inflammatory	NULL
.	NULL

There	NULL
was	NULL
no	NULL
effect	NULL
on	NULL
IL-10	NULL
or	NULL
IL-lra	NULL
production	NULL
,	NULL
some	NULL
modest	NULL
up-regulation	NULL
of	NULL
IL-11	NULL
,	NULL
and	NULL
only	NULL
a	NULL
moderate	NULL
reduction	NULL
of	NULL
the	NULL
p75	NULL
soluble	NULL
TNF-R	NULL
,	NULL
assayed	NULL
two	NULL
days	NULL
after	NULL
AdvI	NULL
«	NULL
Ba	NULL
infection	NULL
.	NULL

Because	NULL
the	NULL
p75	NULL
soluble	NULL
TNF-R	NULL
is	NULL
markedly	NULL
up-regulated	NULL
by	NULL
pro-inflammatory	NULL
mediators	NULL
(	NULL
lipopolysaccharide	NULL
and	NULL
4	NULL
$	NULL
-phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
as	NULL
well	NULL
as	NULL
IL-1	NULL
and	NULL
TNFa	NULL
)	NULL
(	NULL
36	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
much	NULL
of	NULL
the	NULL
inhibition	NULL
seen	NULL
in	NULL
p75	NULL
is	NULL
secondary	NULL
to	NULL
the	NULL
reduced	NULL
inflammatory	NULL
effects	NULL
after	NULL
AdvI	NULL
«	NULL
kBa	NULL
infection	NULL
.	NULL

Many	NULL
symptoms	NULL
in	NULL
patients	NULL
with	NULL
RA-pain	NULL
,	NULL
stiffness	NULL
,	NULL
and	NULL
joint	NULL
swelling-depend	NULL
on	NULL
pro-inflammatory	NULL
cytokines	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
rapid	NULL
onset	NULL
of	NULL
benefit	NULL
after	NULL
anti-TNFa	NULL
therapy	NULL
(	NULL
1-6	NULL
)	NULL
.	NULL

Just	NULL
as	NULL
important	NULL
,	NULL
if	NULL
not	NULL
more	NULL
so	NULL
,	NULL
is	NULL
the	NULL
process	NULL
of	NULL
joint	NULL
destruction	NULL
.	NULL

In	NULL
mice	NULL
with	NULL
collagen	NULL
induced	NULL
arthritis	NULL
or	NULL
with	NULL
a	NULL
disregulated	NULL
TNFa	NULL
transgene	NULL
,	NULL
there	NULL
is	NULL
joint	NULL
destruction	NULL
that	NULL
can	NULL
be	NULL
abolished	NULL
by	NULL
blocking	NULL
TNFa	NULL
and	NULL
other	NULL
pro-inflammatory	NULL
cytokines	NULL
(	NULL
37-39	NULL
)	NULL
.	NULL

However	NULL
,	NULL
whether	NULL
this	NULL
is	NULL
the	NULL
case	NULL
in	NULL
RA	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
enzymes	NULL
involved	NULL
in	NULL
the	NULL
breakdown	NULL
of	NULL
human	NULL
articular	NULL
cartilage	NULL
,	NULL
composed	NULL
primarily	NULL
of	NULL
collagen	NULL
type	NULL
II	NULL
and	NULL
proteoglycans	NULL
,	NULL
in	NULL
RA	NULL
has	NULL
been	NULL
the	NULL
focus	NULL
of	NULL
multiple	NULL
studies	NULL
during	NULL
the	NULL
last	NULL
decades	NULL
and	NULL
is	NULL
still	NULL
a	NULL
subject	NULL
of	NULL
debate	NULL
(	NULL
25	NULL
)	NULL
.	NULL

There	NULL
is	NULL
evidence	NULL
that	NULL
MMPs	NULL
,	NULL
in	NULL
particular	NULL
MMP	NULL
1	NULL
,	NULL
MMP	NULL
13	NULL
,	NULL
and	NULL
the	NULL
membrane-bound	NULL
MMPs	NULL
,	NULL
are	NULL
capable	NULL
of	NULL
cleaving	NULL
collagen	NULL
type	NULL
II	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

MMP	NULL
3	NULL
lacks	NULL
this	NULL
capacity	NULL
but	NULL
does	NULL
have	NULL
activity	NULL
against	NULL
other	NULL
components	NULL
of	NULL
the	NULL
extracellular	NULL
matrix	NULL
,	NULL
including	NULL
proteoglycans	NULL
,	NULL
fibronectin	NULL
,	NULL
and	NULL
laminin	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
MMP	NULL
3	NULL
or	NULL
other	NULL
MMP	NULL
enzymes	NULL
in	NULL
proteoglycan	NULL
cleavage	NULL
is	NULL
still	NULL
a	NULL
matter	NULL
of	NULL
debate	NULL
.	NULL

AP-1	NULL
has	NULL
been	NULL
proposed	NULL
as	NULL
the	NULL
dominant	NULL
transcription	NULL
factor	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
because	NULL
there	NULL
are	NULL
AP-1	NULL
sites	NULL
on	NULL
both	NULL
promoters	NULL
and	NULL
deletion	NULL
of	NULL
AP-1	NULL
site	NULL
(	NULL
s	NULL
)	NULL
inhibited	NULL
MMP	NULL
gene	NULL
activation	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
certain	NULL
agents	NULL
that	NULL
block	NULL
AP-1	NULL
also	NULL
inhibit	NULL
the	NULL
synthesis	NULL
of	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Other	NULL
authors	NULL
(	NULL
44-46	NULL
)	NULL
have	NULL
demonstrated	NULL
AP-1-independent	NULL
mechanisms	NULL
of	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
induction	NULL
,	NULL
however	NULL
,	NULL
and	NULL
some	NULL
recent	NULL
studies	NULL
(	NULL
47-49	NULL
)	NULL
have	NULL
discussed	NULL
whether	NULL
NF-kB	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
MMP	NULL
1	NULL
induction	NULL
.	NULL

We	NULL
investigated	NULL
whether	NULL
NF-	NULL
«	NULL
B	NULL
blockade	NULL
modulated	NULL
the	NULL
synthesis	NULL
of	NULL
MMP	NULL
enzymes	NULL
or	NULL
TIMP-1	NULL
,	NULL
the	NULL
inducible	NULL
tissue	NULL
inhibitor	NULL
of	NULL
MMPs	NULL
,	NULL
which	NULL
binds	NULL
covalently	NULL
and	NULL
irreversibly	NULL
inactivates	NULL
the	NULL
enzymatic	NULL
site	NULL
of	NULL
MMPs	NULL
.	NULL

AdvI	NULL
«	NULL
kBa	NULL
markedly	NULL
inhibited	NULL
the	NULL
degradative	NULL
enzymes	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
TIMP-1	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
destructive	NULL
potential	NULL
of	NULL
the	NULL
synovium	NULL
is	NULL
markedly	NULL
reduced	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
blockade	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
,	NULL
in	NULL
this	NULL
context	NULL
,	NULL
that	NULL
the	NULL
promoter	NULL
element	NULL
of	NULL
MMP	NULL
1	NULL
has	NULL
several	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
(	NULL
47	NULL
,	NULL
50	NULL
,	NULL
51	NULL
)	NULL
and	NULL
that	NULL
our	NULL
own	NULL
data	NULL
indicate	NULL
that	NULL
MMP	NULL
1	NULL
is	NULL
NF-	NULL
«	NULL
B-dependent	NULL
in	NULL
fibroblasts	NULL
and	NULL
chondro-sarcoma	NULL
cells	NULL
(	NULL
J.B.	NULL
,	NULL
F.B	NULL
.	NULL

,	NULL
B.F.	NULL
,	NULL
and	NULL
MF	NULL
.	NULL

,	NULL
unpublished	NULL
work	NULL
)	NULL
,	NULL
which	NULL
do	NULL
not	NULL
produce	NULL
IL-1	NULL
and	NULL
TNFa	NULL
.	NULL

The	NULL
MMP	NULL
3	NULL
promoter	NULL
has	NULL
just	NULL
one	NULL
site	NULL
(	NULL
GenBank	NULL
accession	NULL
no	NULL
.	NULL

U43511	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
whether	NULL
the	NULL
inhibition	NULL
of	NULL
MMP	NULL
3	NULL
seen	NULL
after	NULL
Advi	NULL
«	NULL
kBa	NULL
infection	NULL
is	NULL
direct	NULL
or	NULL
indirect	NULL
,	NULL
just	NULL
reflecting	NULL
the	NULL
reductions	NULL
in	NULL
IL-1	NULL
and	NULL
TNFa	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
here	NULL
indicate	NULL
that	NULL
blocking	NULL
NF-kB	NULL
in	NULL
rheumatoid	NULL
joints	NULL
would	NULL
have	NULL
an	NULL
uniquely	NULL
beneficial	NULL
profile-within	NULL
2	NULL
days	NULL
,	NULL
there	NULL
is	NULL
marked	NULL
reduction	NULL
in	NULL
the	NULL
pro-inflammatory	NULL
cytokines	NULL
,	NULL
without	NULL
a	NULL
concomitant	NULL
reduction	NULL
in	NULL
the	NULL
anti-inflammatory	NULL
mediators	NULL
.	NULL

This	NULL
should	NULL
have	NULL
a	NULL
markedly	NULL
beneficial	NULL
effect	NULL
on	NULL
the	NULL
synovitis	NULL
especially	NULL
in	NULL
the	NULL
light	NULL
of	NULL
the	NULL
considerable	NULL
``	NULL
downstream	NULL
``	NULL
effects	NULL
of	NULL
blocking	NULL
the	NULL
single	NULL
cytokine	NULL
TNFa	NULL
,	NULL
as	NULL
discussed	NULL
(	NULL
5	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Just	NULL
as	NULL
importantly	NULL
,	NULL
the	NULL
destructive	NULL
metalloproteinase	NULL
enzymes	NULL
MMP	NULL
1	NULL
and	NULL
MMP	NULL
3	NULL
are	NULL
reduced	NULL
,	NULL
without	NULL
a	NULL
concomitant	NULL
reduction	NULL
in	NULL
their	NULL
inducible	NULL
inhibitor	NULL
,	NULL
TIMP-1	NULL
.	NULL

Hence	NULL
,	NULL
drugs	NULL
that	NULL
block	NULL
NF-kB	NULL
in	NULL
the	NULL
diseased	NULL
synovial	NULL
tissue	NULL
should	NULL
inhibit	NULL
both	NULL
synovitis	NULL
and	NULL
joint	NULL
Immunology	NULL
:	NULL
Bondeson	NULL
et	NULL
al	NULL
destruction	NULL
.	NULL

Although	NULL
none	NULL
are	NULL
yet	NULL
known	NULL
to	NULL
be	NULL
both	NULL
safe	NULL
and	NULL
effective	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
some	NULL
will	NULL
be	NULL
found	NULL
because	NULL
of	NULL
intense	NULL
screening	NULL
efforts	NULL
in	NULL
the	NULL
pharmaceutical	NULL
industry	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
above	NULL
data	NULL
and	NULL
finding	NULL
of	NULL
nuclear	NULL
NF-KB	NULL
in	NULL
active	NULL
RA	NULL
joints	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
seems	NULL
to	NULL
be	NULL
central	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
RA	NULL
and	NULL
perhaps	NULL
other	NULL
chronic	NULL
inflammatory	NULL
dis-eases	NULL
.	NULL

There	NULL
is	NULL
much	NULL
excitement	NULL
in	NULL
the	NULL
pharmaceutical	NULL
industry	NULL
about	NULL
the	NULL
power	NULL
of	NULL
``	NULL
genomics	NULL
``	NULL
approaches	NULL
to	NULL
define	NULL
candidate	NULL
genes	NULL
as	NULL
potential	NULL
therapeutic	NULL
targets	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
a	NULL
dearth	NULL
of	NULL
techniques	NULL
to	NULL
rapidly	NULL
assess	NULL
which	NULL
,	NULL
if	NULL
any	NULL
,	NULL
of	NULL
the	NULL
potential	NULL
candidates	NULL
are	NULL
worth	NULL
pursuing	NULL
further	NULL
.	NULL

By	NULL
bridging	NULL
genetic	NULL
and	NULL
functional	NULL
approaches	NULL
,	NULL
adenovirus	NULL
as	NULL
used	NULL
here	NULL
provides	NULL
a	NULL
way	NULL
of	NULL
accelerating	NULL
therapeutic	NULL
development	NULL
.	NULL

Because	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
generate	NULL
a	NULL
wide	NULL
spectrum	NULL
of	NULL
inhibitors	NULL
by	NULL
molecular	NULL
approaches	NULL
,	NULL
such	NULL
as	NULL
antisense	NULL
cDNA	NULL
,	NULL
dominant	NULL
negative	NULL
kinases	NULL
,	NULL
or	NULL
single	NULL
chain	NULL
Fv	NULL
antibodies	NULL
,	NULL
this	NULL
adenoviral	NULL
approach	NULL
has	NULL
the	NULL
power	NULL
to	NULL
ascertain	NULL
what	NULL
a	NULL
specific	NULL
and	NULL
potent	NULL
drug	NULL
blocking	NULL
a	NULL
certain	NULL
pathway	NULL
would	NULL
achieve	NULL
at	NULL
the	NULL
actual	NULL
disease	NULL
site	NULL
.	NULL

We	NULL
thank	NULL
Professor	NULL
R.	NULL
N.	NULL
Maini	NULL
for	NULL
his	NULL
encouragement	NULL
and	NULL
helpful	NULL
suggestions	NULL
.	NULL

The	NULL
Advi	NULL
«	NULL
kBa	NULL
adenovirus	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Rainer	NULL
de	NULL
Martin	NULL
(	NULL
Department	NULL
of	NULL
Vascular	NULL
Biology	NULL
and	NULL
Thrombosis	NULL
Research	NULL
,	NULL
University	NULL
of	NULL
Vienna	NULL
,	NULL
Austria	NULL
)	NULL
.	NULL

This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
the	NULL
Arthritis	NULL
Research	NULL
Campaign	NULL
(	NULL
U.K.	NULL
)	NULL
,	NULL
the	NULL
Wellcome	NULL
Trust	NULL
,	NULL
the	NULL
European	NULL
Community	NULL
Training	NULL
and	NULL
Mobility	NULL
of	NULL
Researchers	NULL
Fellowships	NULL
,	NULL
and	NULL
the	NULL
Swedish	NULL
Institute	NULL
.	NULL

1	NULL
.	NULL

Elliott	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
,	NULL
Long-Fox	NULL
,	NULL
A.	NULL
,	NULL
Charles	NULL
,	NULL
P.	NULL
,	NULL
Katsikis	NULL
,	NULL
P.	NULL
,	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Walker	NULL
,	NULL
J.	NULL
,	NULL
Bijl	NULL
,	NULL
H.	NULL
,	NULL
Ghrayeb	NULL
,	NULL
J.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

36	NULL
,	NULL
1681-1690	NULL
.	NULL

2	NULL
.	NULL

Elliott	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
,	NULL
Kalden	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Antoni	NULL
,	NULL
C.	NULL
,	NULL
Smolen	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Leeb	NULL
,	NULL
B.	NULL
,	NULL
Breedveld	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Macfarlane	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Bijl	NULL
,	NULL
H.	NULL
,	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Lancet	NULL
344	NULL
,	NULL
1105-1110	NULL
.	NULL

3	NULL
.	NULL

Rankin	NULL
,	NULL
E.	NULL
C.	NULL
C.	NULL
,	NULL
Choy	NULL
,	NULL
E.	NULL
H.	NULL
S.	NULL
,	NULL
Kassimos	NULL
,	NULL
D.	NULL
,	NULL
Kingsley	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Sopwith	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Isenberg	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

&	NULL
Panayi	NULL
,	NULL
G.	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

34	NULL
,	NULL
334-342	NULL
.	NULL

4	NULL
.	NULL

Moreland	NULL
,	NULL
L.	NULL
W.	NULL
,	NULL
Baumgartner	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Schiff	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Tindall	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Fleischmann	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Weaver	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Ettlinger	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Cohen	NULL
,	NULL
S.	NULL
,	NULL
Koopman	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Mohler	NULL
,	NULL
K.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

337	NULL
,	NULL
141-147	NULL
.	NULL

5	NULL
.	NULL

-	NULL
Feldmann	NULL
,	NULL
M.	NULL
,	NULL
Elliott	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Woody	NULL
,	NULL
J.	NULL
N.	NULL
&	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

64	NULL
,	NULL
283-350	NULL
.	NULL

6	NULL
.	NULL

-	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Breedveld	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Kalden	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Smolen	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Davis	NULL
,	NULL
D.	NULL
,	NULL
Macfarlane	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Antoni	NULL
,	NULL
C.	NULL
,	NULL
Leeb	NULL
,	NULL
B.	NULL
,	NULL
Elliott	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Woody	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

41	NULL
,	NULL
1552-1563	NULL
.	NULL

7	NULL
.	NULL

Van	NULL
Lent	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
Van	NULL
De	NULL
Loo	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
Holthuysen	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Van	NULL
Den	NULL
Bersselaar	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Vermeer	NULL
,	NULL
H.	NULL
&	NULL
Van	NULL
Den	NULL
Berg	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Rheumatol	NULL
.	NULL

22	NULL
,	NULL
2250-2258	NULL
.	NULL

8	NULL
.	NULL

Zvaifler	NULL
,	NULL
N.	NULL
J	NULL
.	NULL

&	NULL
Firestein	NULL
,	NULL
G.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

37	NULL
,	NULL
783-789	NULL
.	NULL

9	NULL
.	NULL

-	NULL
Muller-Ladner	NULL
,	NULL
U.	NULL
,	NULL
Kriegsmann	NULL
,	NULL
J.	NULL
,	NULL
Franklin	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Matsumoto	NULL
,	NULL
S.	NULL
,	NULL
Geiler	NULL
,	NULL
T.	NULL
,	NULL
Gay	NULL
,	NULL
R.	NULL
E.	NULL
&	NULL
Gay	NULL
,	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

149	NULL
,	NULL
1607-1615	NULL
.	NULL

10	NULL
.	NULL

Foxwell	NULL
,	NULL
B.	NULL
M.	NULL
J.	NULL
,	NULL
Browne	NULL
,	NULL
K.	NULL
,	NULL
Bondeson	NULL
,	NULL
J.	NULL
,	NULL
Clarke	NULL
,	NULL
C.	NULL
,	NULL
de	NULL
Martin	NULL
,	NULL
R.	NULL
,	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Nail	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
,	NULL
8211-8215	NULL
.	NULL

11	NULL
.	NULL

Bondeson	NULL
,	NULL
J.	NULL
,	NULL
Brown	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Foxwell	NULL
,	NULL
B.	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

162	NULL
,	NULL
2939-2945	NULL
.	NULL

12	NULL
.	NULL

Buchan	NULL
,	NULL
G.	NULL
,	NULL
Barrett	NULL
,	NULL
K.	NULL
,	NULL
Turner	NULL
,	NULL
M.	NULL
,	NULL
Chantry	NULL
,	NULL
D.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

73	NULL
,	NULL
449-455	NULL
.	NULL

13	NULL
.	NULL

Wrighton	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Hofer-Warbinek	NULL
,	NULL
R.	NULL
,	NULL
Moll	NULL
,	NULL
T.	NULL
,	NULL
Eytner	NULL
,	NULL
R.	NULL
,	NULL
Bach	NULL
,	NULL
F.	NULL
H.	NULL
&	NULL
de	NULL
Martin	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
1013-1022	NULL
.	NULL

14	NULL
.	NULL

Graham	NULL
,	NULL
F.	NULL
L.	NULL
&	NULL
Prevec	NULL
,	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Biotechnol	NULL
.	NULL

3	NULL
,	NULL
207-220	NULL
.	NULL

15	NULL
.	NULL

Clarke	NULL
,	NULL
C.	NULL
J.	NULL
P.	NULL
,	NULL
Taylor-Fishwick	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Hales	NULL
,	NULL
A.	NULL
,	NULL
Chernajovsky	NULL
,	NULL
Y.	NULL
,	NULL
Sugamura	NULL
,	NULL
K.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
&	NULL
Foxwell	NULL
,	NULL
B.	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
2961-2966	NULL
.	NULL

16	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Nicolas	NULL
,	NULL
J.	NULL
F.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
2603-2607	NULL
.	NULL

17	NULL
.	NULL

Engelberts	NULL
,	NULL
I.	NULL
,	NULL
Moller	NULL
,	NULL
A.	NULL
,	NULL
Schoen	NULL
,	NULL
G.	NULL
J.	NULL
M.	NULL
,	NULL
van	NULL
der	NULL
Linden	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Buurman	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Lymphokine	NULL
Cytokine	NULL
Res	NULL
.	NULL

10	NULL
,	NULL
60-76	NULL
.	NULL

18	NULL
.	NULL

Butler	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
&	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

Cytokine	NULL
Network	NULL
6	NULL
,	NULL
225-230	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
5673	NULL
Abrams	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Ronocarlo	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Yssel	NULL
,	NULL
H.	NULL
,	NULL
Andersson	NULL
,	NULL
U.	NULL
,	NULL
Gleich	NULL
,	NULL
G.	NULL
I	NULL
.	NULL

&	NULL
Silver	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

125	NULL
,	NULL
5-24	NULL
.	NULL

Foey	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Parry	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Williams	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
,	NULL
Foxwell	NULL
,	NULL
B.	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
920-928	NULL
.	NULL

Hermann	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hall	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
&	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

41	NULL
,	NULL
1388-1397	NULL
.	NULL

Bauerle	NULL
,	NULL
P.	NULL
&	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

Whiteside	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
Visvanathan	NULL
,	NULL
K.	NULL
V.	NULL
&	NULL
Goodbourn	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20	NULL
,	NULL
1531-1538	NULL
.	NULL

Katsikis	NULL
,	NULL
P.	NULL
,	NULL
Chu	NULL
,	NULL
C.	NULL
Q.	NULL
,	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179	NULL
,	NULL
1517-1527	NULL
.	NULL

Matrisian	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

6	NULL
,	NULL
121-125	NULL
.	NULL

Clark	NULL
,	NULL
I.	NULL
H.	NULL
,	NULL
Powell	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Ramsey	NULL
,	NULL
S.	NULL
,	NULL
Hazleman	NULL
,	NULL
B.	NULL
L.	NULL
&	NULL
Cawston	NULL
,	NULL
T.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Arthritis	NULL
.	NULL

Rheum	NULL
.	NULL

36	NULL
,	NULL
372-379	NULL
.	NULL

Manicourt	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Fujimoto	NULL
,	NULL
N.	NULL
,	NULL
Obata	NULL
,	NULL
K.	NULL
&	NULL
Thonar	NULL
,	NULL
E.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

38	NULL
,	NULL
1031-1039	NULL
.	NULL

Brennan	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Browne	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Green	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Jasper	NULL
,	NULL
J.-M.	NULL
,	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

36	NULL
,	NULL
643-650	NULL
.	NULL

DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hayakawa	NULL
,	NULL
M.	NULL
,	NULL
Rothwarf	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Zandi	NULL
,	NULL
E.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
388	NULL
,	NULL
548-554	NULL
.	NULL

Woronicz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Gao	NULL
,	NULL
X.	NULL
,	NULL
Cao	NULL
,	NULL
Z.	NULL
,	NULL
Rothe	NULL
,	NULL
M.	NULL
&	NULL
D.	NULL
V.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
866-869	NULL
.	NULL

Huang	NULL
,	NULL
S.	NULL
,	NULL
Endo	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

&	NULL
Nemerow	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
2257-2263	NULL
.	NULL

Wickham	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Lee	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Titus	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Sconocchia	NULL
,	NULL
G.	NULL
,	NULL
Bakacs	NULL
,	NULL
T.	NULL
,	NULL
Kovesdi	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Segal	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
7663-7669	NULL
.	NULL

Mentel	NULL
,	NULL
R.	NULL
,	NULL
Dopping	NULL
,	NULL
G.	NULL
,	NULL
Wegner	NULL
,	NULL
U.	NULL
,	NULL
Seidel	NULL
,	NULL
W.	NULL
,	NULL
Liebermann	NULL
,	NULL
H.	NULL
&	NULL
Dohner	NULL
,	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

51	NULL
,	NULL
252-257	NULL
.	NULL

Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
&	NULL
Doyle	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174	NULL
,	NULL
73-81	NULL
.	NULL

Feldmann	NULL
,	NULL
M.	NULL
,	NULL
Brennan	NULL
,	NULL
F.	NULL
M.	NULL
&	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
397-440	NULL
.	NULL

Pennica	NULL
,	NULL
D.	NULL
,	NULL
Lam	NULL
,	NULL
V.	NULL
T.	NULL
,	NULL
Mize	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Weber	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
Lewis	NULL
,	NULL
M.	NULL
,	NULL
Fendly	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Lipari	NULL
,	NULL
M.	NULL
T.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
21172-21178	NULL
.	NULL

Thorbecke	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Shah	NULL
,	NULL
R.	NULL
,	NULL
Leu	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Kuruvilla	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
Hardison	NULL
,	NULL
A.	NULL
M.	NULL
&	NULL
Palladino	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
7375-7379	NULL
.	NULL

Williams	NULL
,	NULL
R.	NULL
O.	NULL
,	NULL
Feldmann	NULL
,	NULL
M.	NULL
&	NULL
Maini	NULL
,	NULL
R.	NULL
N.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
9784-9788	NULL
.	NULL

Kollias	NULL
,	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

144	NULL
,	NULL
342-347	NULL
.	NULL

Knauper	NULL
,	NULL
V.	NULL
,	NULL
Cowell	NULL
,	NULL
S.	NULL
,	NULL
Smith	NULL
,	NULL
B.	NULL
,	NULL
Lopez-Otin	NULL
,	NULL
C.	NULL
,	NULL
O'Shea	NULL
,	NULL
M	NULL
,	NULL
Morris	NULL
,	NULL
H.	NULL
,	NULL
Zardi	NULL
,	NULL
L.	NULL
&	NULL
Murphy	NULL
,	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
7608-7616	NULL
.	NULL

Cowell	NULL
,	NULL
S.	NULL
,	NULL
Knauper	NULL
,	NULL
V.	NULL
,	NULL
Stewart	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
D'Ortho	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Stanton	NULL
,	NULL
H.	NULL
,	NULL
Hembry	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Lopez-Otin	NULL
,	NULL
C.	NULL
,	NULL
Reynolds	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

&	NULL
Murphy	NULL
,	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

331	NULL
,	NULL
453-458	NULL
.	NULL

Fini	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Cook	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Mohan	NULL
,	NULL
R.	NULL
&	NULL
Brinckerhoff	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
in	NULL
Matrix	NULL
Metalloproteinases	NULL
,	NULL
eds	NULL
.	NULL

Parks	NULL
,	NULL
W.	NULL
C.	NULL
&	NULL
Mecham	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
Academic	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

299-356	NULL
.	NULL

Hui	NULL
,	NULL
A.	NULL
,	NULL
Min	NULL
,	NULL
W.	NULL
X.	NULL
,	NULL
Tang	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Cruz	NULL
,	NULL
T.	NULL
F.	NULL
(	NULL
1998	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

41	NULL
,	NULL
869-876	NULL
.	NULL

Buttice	NULL
,	NULL
G.	NULL
,	NULL
Quinones	NULL
,	NULL
S.	NULL
&	NULL
Kurkinen	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
3723-3731	NULL
.	NULL

Quinones	NULL
,	NULL
S.	NULL
,	NULL
Buttice	NULL
,	NULL
G.	NULL
&	NULL
Kurkinen	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

302	NULL
,	NULL
471-477	NULL
.	NULL

Borghaei	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Rawlings	NULL
,	NULL
P.	NULL
L.	NULL
&	NULL
Mochan	NULL
,	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

41	NULL
,	NULL
1398-1406	NULL
.	NULL

Tewari	NULL
,	NULL
M.	NULL
,	NULL
Tuncay	NULL
,	NULL
O.	NULL
C.	NULL
,	NULL
Milchman	NULL
,	NULL
A.	NULL
,	NULL
Reddy	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Reddy	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Cressman	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Taub	NULL
,	NULL
R.	NULL
,	NULL
Newton	NULL
,	NULL
R.	NULL
C.	NULL
&	NULL
Tewari	NULL
,	NULL
D.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Arch	NULL
.	NULL

Oral	NULL
Biol	NULL
.	NULL

41	NULL
,	NULL
461-468	NULL
.	NULL

Borghaei	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Borghaci	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Ni	NULL
,	NULL
X.	NULL
,	NULL
Pease	NULL
,	NULL
E.	NULL
,	NULL
Thornton	NULL
,	NULL
R.	NULL
&	NULL
Mochan	NULL
,	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
Inflamm	NULL
.	NULL

Res	NULL
.	NULL

46	NULL
,	NULL
S177-	NULL
$	NULL
178	NULL
.	NULL

Reddy	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Tewari	NULL
,	NULL
M.	NULL
,	NULL
Hamid	NULL
,	NULL
Q	NULL
.	NULL

A.	NULL
,	NULL
Tuncay	NULL
,	NULL
O.	NULL
C.	NULL
&	NULL
Tewari	NULL
,	NULL
D.	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

218	NULL
,	NULL
238-243	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
.	NULL

Vincenti	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Coon	NULL
,	NULL
C.	NULL
I	NULL
.	NULL

&	NULL
Brinckerhoff	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

41	NULL
,	NULL
1987-1994	NULL
.	NULL

Marok	NULL
,	NULL
R.	NULL
,	NULL
Winyard	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Coumbe	NULL
,	NULL
A.	NULL
,	NULL
Kus	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Gaffney	NULL
,	NULL
K.	NULL
,	NULL
Blades	NULL
,	NULL
S.	NULL
,	NULL
Mapp	NULL
,	NULL
P.	NULL
I.	NULL
,	NULL
Morris	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Blake	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Kaltschmidt	NULL
,	NULL
C.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

39	NULL
,	NULL
583-591	NULL
.	NULL

Sioud	NULL
,	NULL
M.	NULL
,	NULL
Mellbye	NULL
,	NULL
O	NULL
.	NULL

&	NULL
Forre	NULL
,	NULL
O	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Rheumatol	NULL
.	NULL

16	NULL
,	NULL
125-134	NULL
.	NULL

